Change of QRS Morphology and Electrophysiological Characteristics During Pacing Within the Interventricular Septum

March 15, 2023 updated by: Yanchun Liang, General Hospital of Shenyang Military Region

Change of QRS Morphology and Electrophysiological Characteristics During Pacing Within the Interventricular Septum: a Prospective, Observational Study

Conduction system pacing (CSP), including His bundle pacing (HBP) and left bundle branch (LBB) pacing (LBBP), as a physiological pacing strategy, can achieve interventricular and/or intra-left ventricular mechanical synchronization by delivering physiological or nearly physiological ventricular activation. And many studies have verifed clinical efficacy of CSP that it can significantly relieve dyssynchrony of ventricular contraction, improve cardiac function and reduce the risk of heart failure as compared to right ventricular pacing. However, CSP has some shortcomings which limit its widespread application to some extent. As for HBP, although it can achieve optimal physiological ventricular synchronization, the problems of relatively high pacing threshold, low R-wave amplitude, the long-term performance, and inability to correct infra-Hisian atrioventricular block and intraventricular block in some patients have always been concerns. Nevertheless, LBBP is likely free of the restrictions mentioned above. On the contrary, LBBP can capture the left conduction system by directly stimulating the proximal LBB distal to the site of conduction block, thereby achieving rapid and physiological LV activation with a lower and stable pacing threshold and higher R-wave amplitude. However, as a newly emerged physiologic pacing technology, LBBP is currently in the exploratory stage and there are some phenomena to be interpreted, such as the evolution of pacing QRS morphology during the lead penetration into the interventricular septum. Therefore, the aim of this study is to assess the morphological evolution and electrophysiological characteristics of various pacing QRS patterns observed as the lead penetrates the interventricular septum from right to left.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Anticipated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Liaoning
      • Shenyang, Liaoning, China, 110016
        • Recruiting
        • General Hospital of Northern Theater Command
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients requiring a high percentage of ventricular pacing (>40% expected ventricular pacing) include patients with advanced or third-degree atrioventricular block and atrial fibrillation with bradycardia.

Description

Inclusion Criteria:

  • The indications for pacemaker implantation are in accordance with the 2021 European Society of Cardiology (ESC) guidelines.
  • Patients requiring a high percentage of ventricular pacing (>40% expected ventricular pacing) include patients with advanced or third-degree atrioventricular block and atrial fibrillation with bradycardia.
  • Left bundle branch pacing will be performed.
  • Patients voluntarily participate and sign informed consent.

Exclusion Criteria:

  • Atrioventricular block caused by reversible factors such as acute myocardial infarction and electrolyte disturbance.
  • Patients with severe liver or renal failure.
  • Life expectancy < 1 year.
  • Patients with age < 18 years.
  • Left ventricular ejection fraction (LVEF) < 40%.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
All patients
Patients who meet the inclusion criteria
In the procedure of left bundle branch pacing, various QRS morphologies are observed as penetrating the lead into the interventricular septum.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Left ventricular activation time (LVAT)
Time Frame: Continuous uninterrupted monitoring during the lead penetration into the interventricular septum.
Left ventricular activation time (LVAT) is defined as the interval from the onset of the pacing stimulus to the peak of the R wave in lead V5/6, which reflects the lateral precordial myocardium depolarization time.
Continuous uninterrupted monitoring during the lead penetration into the interventricular septum.
Right ventricular activation time (RVAT)
Time Frame: Continuous uninterrupted monitoring during the lead penetration into the interventricular septum.
Right ventricular activation time (RVAT) is defined as the interval from the onset of the pacing stimulus to the peak potential recorded by the atrial electrode temporarily placed in the right ventricle, which reflects delayed right ventricular activation.
Continuous uninterrupted monitoring during the lead penetration into the interventricular septum.
Paced QRS morphology
Time Frame: Continuous uninterrupted monitoring during the lead penetration into the interventricular septum.
Paced QRS morphology during lead penetration through the interventricular septum mainly includes left bundle branch block, intraventricular block and right bundle branch block.
Continuous uninterrupted monitoring during the lead penetration into the interventricular septum.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Stimulus-QRSend duration (s-QRSend)
Time Frame: Continuous uninterrupted monitoring during the lead penetration into the interventricular septum.
Stimulus-QRSend duration (s-QRSend) is the time from the onset of the pacing stimulus to the end of QRS complex.
Continuous uninterrupted monitoring during the lead penetration into the interventricular septum.
The late-R wave duration and amplitude in lead V1 (r´dur、r´amp)
Time Frame: Continuous uninterrupted monitoring during the lead penetration into the interventricular septum.
The late-R wave duration in lead V1 indicates delayed right ventricular excitation.
Continuous uninterrupted monitoring during the lead penetration into the interventricular septum.
The S wave duration and amplitude in lead V6 (Sdur、Samp)
Time Frame: Continuous uninterrupted monitoring during the lead penetration into the interventricular septum.
The S wave duration in lead V6 indicates delayed right ventricular excitation.
Continuous uninterrupted monitoring during the lead penetration into the interventricular septum.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Yanchun Liang, MD、PhD, The General Hospital of Northern Theater Command

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 27, 2022

Primary Completion (Anticipated)

May 1, 2024

Study Completion (Anticipated)

May 1, 2024

Study Registration Dates

First Submitted

September 19, 2022

First Submitted That Met QC Criteria

September 22, 2022

First Posted (Actual)

September 27, 2022

Study Record Updates

Last Update Posted (Actual)

March 16, 2023

Last Update Submitted That Met QC Criteria

March 15, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiac Pacing

Clinical Trials on left bundle branch pacing

3
Subscribe